Diagnostic approach to sepsis - State of the art;Aktuelle aspekte zur sepsisdiagnose

Zentralblatt fur Chirurgie

Volumn 127, Issue 3, 2002, Pages 165-173

  Brunkhorst, F M ^a   Karzai, W ^a   Reinhart, Konrad ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Early diagnosis; Markers; Sepsis; Severe sepsis

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3A; CYTOKINE; ENDOTOXIN; HLA DR ANTIGEN; LEUKOCYTE ELASTASE; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; PHOSPHOLIPASE A2; PROCALCITONIN; PROTEIN C;

ARTICLE; BACTERIUM CULTURE; BODY TEMPERATURE; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; HUMAN; INFLAMMATION; MULTIPLE ORGAN FAILURE; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; PROGNOSIS; PROTEIN PRECURSORS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0036218857     PISSN: 0044409X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-24246     Document Type: Article

References (86)

1. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation
2. Procalcitonin in diagnosis of severe infections
3. Procalcitonin in patients with and without immunosuppression and sepsis
4. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
5. Immunodepression following neurosurgical procedures
6. High serum procalcitonin concentrations in patients with sepsis and infection
7. Serum procalcitonin rise is only slight in two cases of disseminated aspergillosis
8. Efficacy and safety for recombinant human activated protein C for severe sepsis
9. Plasma level and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis
10. Kinetics of procalcitonin in iatrogenic sepsis
11. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock
12. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: The potential importance of bacterial translocation
13. Endotoxin and immunactivation in chronic heart failure
14. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin
15. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates
16. The detection and interpretation of endotoxaemia
17. Procalcitonin increase after endotoxin injection in normal subjects
18. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: Comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia
19. Value of C-reacitve protein measurements in exacerbations of chronic obstructive pulmonary disease
20. Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment
21. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmatic antibody-associated vasculitis) and invasive bacterial infection
22. Procalcitonin in the early phase after renal transplantation: Will it add to diagnostic accuracy?
23. Sensitivity of interleukin-6 and C-reactive protein concentrations in the diagnosis of acute appendicitis
24. Lipopolysaccaride binding protein in acute pancreatitis
25. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients
26. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
27. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases
28. Neopterin as a marker for activated cell-mediated immunity: Application in HIV infection
29. Acute-phase proteins and other systemic responses to inflammation
30. Complement activation and polymorphonuclear neutrophil leucocyte elastase in sepsis
31. Measurement of procalcitonin levels in children with bacterial or viral meningitis
32. Procalcitonin ein neuer marker der inflammatorischen wirtsantwort. Longitudinalstudien bei patienten mit sepsis und peritonitis
33. Activity markers for the inflammatory host response and early criteria of sepsis
34. Increased plasma levels of interleukin-6 in sepsis
35. Increased serum interleukin-8: Correlation with poor prognosis in patients with postoperative multiple organ failure
36. Procalcitonin: A new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation
37. Systemic inflammation in heart failure
38. Monocyte function before and after surgical trauma
39. Elastase in tissue injury
40. Daily serum interleukin-6 monitoring in multiple organtransplantation with or without liver allografts
41. Procalcitonin in fever of unknown origin after liver transplantation: A variable to differentiate acute rejection from infection
42. Study of pro-inflammatory (TNF-alpha, IL1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters
43. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
44. Procalcitonin (PCT) in cardiac surgery
45. Procalcitonin in patients undergoing cardiopulmonary bypass in open heart surgery-first results of the Procalcitonin in Heart Surgery study (ProHearts)
46. Elevation of interleukin-6 in patients with chronic hepatitis due to hepatitis C virus
47. Definition of sepsis
48. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS
49. Postoperative plasma concentrations of procalcitonin after different types of surgery
50. Procalcitonin (PCT) - Ein enuer parameter zur diagnostik und verlaufskontrolle von bakteriellen infektionen und sepsis
51. Procalcitonin Influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations
52. Prognostic value of protein C concentrations at high risk of severe septic complications
53. Procalcitonin and C-reactive protein levels in neonatal infections
54. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis
55. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit
56. Indicators of the posttraumatic inflammatory response correlate with organ failure in patients with multiple injuries
57. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis
58. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis related cytokines in vitro
59. Sensitivity and specifity of various markers of inflammation for the prediction of tumor necrosis factor alpha and interleukin-6 in patients with sepsis
60. Relationship between plasma levels of lipopolysaccaride (LPS) and LPS-binding protein in patients with severe sepsis and septic shock
61. C-reactive protein as an indicator of sepsis
62. Relationship between neopterin and granuolcyte elastase plasma levels and the severity of multiple organ failure
63. Septest, a rapid, immunostrip test for serum IL-6 concentrations, prospectively defined a population of patients with sepsis at greater risk for mortality in the MONARCS (monoclonal anti-TNF: A randomized controlled sepsis) trial
64. How are cytokines activated in heart failure?
65. CD 14 is a pattern recognition receptor
66. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
67. The role of procalcitonin and interleukin-8 in the prediction of infected necrosis in acute pancreatitis
68. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
69. Update on detection of bacteremia and fungemia
70. Septic shock without documented infection: An uncommon entity with a high mortality
71. Procalcitonin in early detection of postoperative complications
72. Group II phospholipases in sera of febrile patients with microbiologically or clinically documented infections
73. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis
74. A rapid assay of endotoxin in whole blood using autologous neutrophil-dependent chemiluminescence
75. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6
76. Serum C-reactive protein and neopterin concentrations in patients with viral or bacterial infections
77. The serum interleukin-6 response to elective surgery
78. CRP levels in autoimmune disease can be specified by measurement of procalcitonin
79. Structure and function of lipopolysaccaride binding protein
80. Procalcitonin used as a marker in the intensive care unit
81. A multicenter study of phospholipase A2 in patients in intensive care units
82. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis
83. Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis
84. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients
85. Group-specific assays that distinguish between the four major types of mammalian phospholipase A2